Peter Lynch fit · Growth at a reasonable price (GARP)
Is Arbutus Biopharma Corporation (ABUS) a Peter Lynch Stock?
Does not fit Lynch's GARP criteria - growth too low or price too high.
11/100
FNot a fit
1/6 criteria passed
Peter Lynch's Criteria, Applied to ABUS
PEG ≤ 1.0
key-
EPS CAGR ≥ 15%
key-
Revenue CAGR ≥ 10%
6.4%
Net margin > 0
-237.9%
How ABUS Scores on Other Strategies
Live Financial Snapshot
Market cap
$859.29M
P/E (TTM)
5.1x
ROIC (TTM)
56.72%
Gross margin
99.98%
Other Peter Lynch fit reports
Frequently Asked Questions
What is ABUS's Peter Lynch fit score?
ABUS scores 11/100 on our Peter Lynch fit engine - grade F. Does not fit Lynch's GARP criteria - growth too low or price too high.
Does Peter Lynch actually own ABUS?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends ABUS.
How often is this score updated?
ABUS's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Peter Lynch personally owns or recommends ABUS.